Alcestobart

DRUG3 trials

Sponsors

BeiGene

Conditions

HNSCC for Phase 2 Dose ExpansionLocally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-inNSCLC for Phase 2 Dose ExpansionNon Small Cell Lung CancerUnresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Phase 1

Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors

CompletedNCT03744468

BeiGeneHNSCC for Phase 2 Dose Expansion, Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, NSCLC for Phase 2 Dose Expansion

Start: 2018-11-13End: 2025-02-06Updated: 2026-04-02

A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

Active, not recruitingNCT05609370

BeiGeneUnresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Start: 2023-01-29End: 2026-12-31Updated: 2026-06-30

Phase 2

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

CompletedNCT05577702

BeiGeneNon Small Cell Lung Cancer

Start: 2023-03-08End: 2025-01-23Updated: 2026-02-09

Related Papers

Abstract CT276: Liberty-201: Maintenance fluoropyrimidine (FP) and bevacizumab with or without anti-lymphocyte activation gene-3 (LAG-3) antibody LBL-007 plus anti-programmed cell death protein-1 (PD-1) antibody tislelizumab (TIS) for patients (pts) with metastatic or unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) colorectal cancer (CRC)

Cancer Research2024-04-05

Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress.

Journal of Clinical Oncology2020-05-2012 citations